Nasal Obstruction and Olfactory Losses

Description

About 13% of US adults, some 30 million people, suffer from nasal sinus disease. Although nasal obstruction and smell loss are two of the major symptoms of the disease that are crucial to disease management, currently there is a lack of clinical tools to effectively evaluate the mechanisms contributing to these symptoms. The proposed study aims to develop novel clinical tools to better evaluate and relieve patients' nasal obstructive symptoms and to enable patients and clinicians to make more informed, personalized decisions regarding treatment strategy.

Conditions

Nasal Obstruction

Study Overview

Study Details

Study overview

About 13% of US adults, some 30 million people, suffer from nasal sinus disease. Although nasal obstruction and smell loss are two of the major symptoms of the disease that are crucial to disease management, currently there is a lack of clinical tools to effectively evaluate the mechanisms contributing to these symptoms. The proposed study aims to develop novel clinical tools to better evaluate and relieve patients' nasal obstructive symptoms and to enable patients and clinicians to make more informed, personalized decisions regarding treatment strategy.

Novel Mechanisms and Therapeutic Approaches for Nasal Obstruction and Olfactory Losses

Nasal Obstruction and Olfactory Losses

Condition
Nasal Obstruction
Intervention / Treatment

-

Contacts and Locations

Columbus

Eye and Ear Institute, 915 Olentangy River Road, ENT, Suite 4000, Columbus, Ohio, United States, 43212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Smell Loss complaints
  • 2. Nasal Obstruction
  • 1. Congenital olfactory losses
  • 2. Nasal polyps, blocking the olfactory cleft
  • 3. Significant atrophy
  • 4. Cystic fibrosis
  • 5. Wegeners or any other connective tissue disorder
  • 6. Head trauma

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Ohio State University,

Kai Zhao, Ph.D, PRINCIPAL_INVESTIGATOR, Associate Professor

Study Record Dates

2028-12-31